CN105473154A - 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途 - Google Patents

修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途 Download PDF

Info

Publication number
CN105473154A
CN105473154A CN201480027148.2A CN201480027148A CN105473154A CN 105473154 A CN105473154 A CN 105473154A CN 201480027148 A CN201480027148 A CN 201480027148A CN 105473154 A CN105473154 A CN 105473154A
Authority
CN
China
Prior art keywords
cancer
seq
mis
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480027148.2A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里夏·K·多纳霍
季米特里奥斯·瓦瓦斯
戴维德·佩潘
米内·范·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Eye and Ear
Original Assignee
General Hospital Corp
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Eye and Ear Infirmary filed Critical General Hospital Corp
Publication of CN105473154A publication Critical patent/CN105473154A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
CN201480027148.2A 2013-03-12 2014-03-12 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途 Pending CN105473154A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361777135P 2013-03-12 2013-03-12
US61/777,135 2013-03-12
PCT/US2014/024010 WO2014164981A1 (en) 2013-03-12 2014-03-12 Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
CN105473154A true CN105473154A (zh) 2016-04-06

Family

ID=51659030

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027148.2A Pending CN105473154A (zh) 2013-03-12 2014-03-12 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途

Country Status (14)

Country Link
US (2) US11084860B2 (https=)
EP (1) EP2968470B1 (https=)
JP (4) JP6698015B2 (https=)
KR (1) KR20160029731A (https=)
CN (1) CN105473154A (https=)
AU (1) AU2014248768A1 (https=)
BR (1) BR112015022181A8 (https=)
CA (1) CA2904978A1 (https=)
DK (1) DK2968470T3 (https=)
ES (1) ES2853935T3 (https=)
HK (1) HK1222331A1 (https=)
MX (1) MX2015011846A (https=)
PL (1) PL2968470T3 (https=)
WO (1) WO2014164981A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107523586A (zh) * 2017-10-20 2017-12-29 广州万孚生物技术股份有限公司 免疫质粒及用于检测抗穆勒氏管激素的单抗、杂交瘤细胞及其制备方法和应用
CN112251444A (zh) * 2020-10-21 2021-01-22 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
CN115554403A (zh) * 2022-08-16 2023-01-03 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用
CN120591344A (zh) * 2025-06-13 2025-09-05 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2853935T3 (es) * 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
US11135269B2 (en) * 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
WO2020044298A1 (en) * 2018-08-30 2020-03-05 Preglem Sa A novel use of the anti-müllerian hormone
WO2020243679A1 (en) * 2019-05-31 2020-12-03 Detti Laura Anti-mullerian hormone receptor binding peptides
WO2021097369A2 (en) * 2019-11-13 2021-05-20 Celmatix Inc. Compositions and methods regulating folliculogenesis for the treatment of ovarian senescence
CN117042723A (zh) * 2021-01-26 2023-11-10 西吉隆医疗股份有限公司 用于诱导抗原特异性免疫耐受的组合物、装置和方法
EP4284414A4 (en) * 2021-01-26 2025-05-14 Sigilon Therapeutics, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES
RU2770003C1 (ru) * 2021-04-05 2022-04-14 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к С-концевому фрагменту антимюллерова гормона

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006695A1 (en) * 1985-10-30 1989-07-27 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
WO2001019387A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
WO2005030963A1 (en) * 2003-09-26 2005-04-07 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
US20100233689A1 (en) * 2007-03-22 2010-09-16 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224A (en) 1837-06-03 Improvement in cotton-presses
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308483D0 (en) 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4753794A (en) 1986-06-24 1988-06-28 The General Hospital Corporation Use of mullerian inhibiting substance as a contraceptive agent
US5010055A (en) 1986-06-24 1991-04-23 The General Hospital Corporation Use of EGF to reverse the contraceptive activity of MIS
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5061641A (en) 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
WO1989010971A1 (en) 1988-05-09 1989-11-16 The United States Of America, As Represented By Th Vector for secretion of proteins directly into periplasm or culture medium
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
JPH02117384A (ja) * 1988-10-26 1990-05-01 Tonen Corp 酵母宿主によるヒト血清アルブミンａの製造
US5661126A (en) 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5641671A (en) 1990-07-06 1997-06-24 Unilever Patent Holdings B.V. Production of active Pseudomonas glumae lipase in homologous or heterologous hosts
WO1992013951A1 (en) 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
WO1997014809A2 (en) 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6361989B1 (en) 1997-10-13 2002-03-26 Novozymes A/S α-amylase and α-amylase variants
US6156552A (en) 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
US6428978B1 (en) * 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
US6323007B1 (en) 1998-09-18 2001-11-27 Novozymes A/S 2,6-β-D-fructan hydrolase enzyme and processes for using the enzyme
US6180367B1 (en) 1998-10-28 2001-01-30 Genentech, Inc. Process for bacterial production of polypeptides
JP4732591B2 (ja) 1999-03-29 2011-07-27 ノボザイムス アクティーゼルスカブ 分枝酵素活性を有するポリペプチド及びそれをコードする核酸
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
US6558939B1 (en) 1999-08-31 2003-05-06 Novozymes, A/S Proteases and variants thereof
US6673352B1 (en) 1999-09-14 2004-01-06 The General Hospital Corporation Use of Mullerian inhibiting substance for treating excess androgen states
DE19944870A1 (de) 1999-09-18 2001-03-29 Aventis Pharma Gmbh Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium
US6617143B1 (en) 1999-10-20 2003-09-09 Novozymes A/S Polypeptides having glucanotransferase activity and nucleic acids encoding same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US6509181B1 (en) 2000-04-14 2003-01-21 Novozymes, A/S Polypeptides having haloperoxide activity
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
CA2457918C (en) 2001-08-20 2013-11-26 David B. Seifer Mullerian inhibiting substance levels and ovarian response
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2006096515A2 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
CA2516364A1 (en) 2005-03-24 2006-09-24 University Of Otago Method of modulation
EP1951277A2 (en) 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
JP2009515832A (ja) 2005-10-26 2009-04-16 オタゴ イノベーション リミテッド 神経変性疾患の治療のためのミュラー管抑制物質（ｍｉｓ）受容体のモジュレーション方法
JP5714230B2 (ja) 2007-01-31 2015-05-07 フェネックス インコーポレイテッド 発現上昇のための細菌リーダー配列
WO2009012357A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
US10457719B2 (en) 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2010017290A1 (en) 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
FR2993926A1 (fr) 2012-07-24 2014-01-31 Vianney Rabhi Turbomoteur basse-pression a combustion interne et/ou externe
ES2853935T3 (es) 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US20240218038A1 (en) 2021-03-22 2024-07-04 The General Hospital Corporation Compositions and methods for preventing or delaying puberty in prepubescent non-human animals and humans

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006695A1 (en) * 1985-10-30 1989-07-27 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
WO2001019387A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
WO2005030963A1 (en) * 2003-09-26 2005-04-07 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
US20100233689A1 (en) * 2007-03-22 2010-09-16 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAPAKOSTAS T D ET AL: "Development of an efficiently cleaved, bioactive,highly pure FLAG-tagged recombinant human Mullerian inhibiting substance", 《PROTEIN EXPR PURIF》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107523586A (zh) * 2017-10-20 2017-12-29 广州万孚生物技术股份有限公司 免疫质粒及用于检测抗穆勒氏管激素的单抗、杂交瘤细胞及其制备方法和应用
CN107523586B (zh) * 2017-10-20 2020-03-17 广州万孚生物技术股份有限公司 免疫质粒及用于检测抗穆勒氏管激素的单抗、杂交瘤细胞及其制备方法和应用
CN112251444A (zh) * 2020-10-21 2021-01-22 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
CN112251444B (zh) * 2020-10-21 2023-05-16 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
CN115554403A (zh) * 2022-08-16 2023-01-03 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用
CN120591344A (zh) * 2025-06-13 2025-09-05 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用

Also Published As

Publication number Publication date
US12497437B2 (en) 2025-12-16
CA2904978A1 (en) 2014-10-09
JP6698015B2 (ja) 2020-05-27
BR112015022181A8 (pt) 2018-01-23
EP2968470A4 (en) 2016-10-12
EP2968470B1 (en) 2020-10-28
MX2015011846A (es) 2016-09-27
BR112015022181A2 (pt) 2017-11-21
KR20160029731A (ko) 2016-03-15
ES2853935T3 (es) 2021-09-20
JP7597511B2 (ja) 2024-12-10
WO2014164981A1 (en) 2014-10-09
HK1222331A1 (zh) 2017-06-30
JP2024178382A (ja) 2024-12-24
DK2968470T3 (da) 2021-02-01
JP2022180637A (ja) 2022-12-06
PL2968470T3 (pl) 2021-05-31
US11084860B2 (en) 2021-08-10
AU2014248768A1 (en) 2015-09-24
US20220041677A1 (en) 2022-02-10
JP2016518325A (ja) 2016-06-23
US20160039898A1 (en) 2016-02-11
JP2020074789A (ja) 2020-05-21
EP2968470A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP7597511B2 (ja) 疾患の治療のための改変されたミュラー管抑制物質（ｍｉｓ）タンパク質およびその使用
US12414966B2 (en) Method of treating diabetes with FGF21 and GLP1 double gene-modified cell
US10258668B2 (en) Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
US20240277812A1 (en) Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
WO2015150922A2 (en) β-HEXOSAMINIDASE PROTEIN VARIANTS AND ASSOCIATED METHODS FOR TREATING GM2 GANGLIOSIDOSES
AU2024203142A1 (en) C3b binding polypeptide
JP2012246296A (ja) 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
CN107810195B (zh) 重组丛生蛋白及其在疾病治疗和预防中的应用
JP2003511028A (ja) 新規ポリペプチド、その核酸および新脈管形成および血管新生におけるその使用のための方法
JP2003517007A (ja) 内皮細胞増殖阻害組成物および方法
HK1052371A1 (en) Airway-specific trypsin-like enzymes and method of using the same
HK40076899A (en) Use of mullerian inhibiting substance (mis) proteins for contraception
CN1518592A (zh) 男用避孕药

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222331

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160406

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1222331

Country of ref document: HK